Trials / Completed
CompletedNCT00574743
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients
A 12-month, Single-blind, Randomized, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of ERL080A Compared With MMF in de Novo Heart Recipients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
This study will evaluate the safety and efficacy of EC-MPS (ERL080) in comparison to MMF in de novo heart recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enteric-coated Mycophenolate Sodium |
Timeline
- Start date
- 2002-01-01
- Primary completion
- 2004-04-01
- First posted
- 2007-12-17
- Last updated
- 2011-11-02
Locations
9 sites across 4 countries: United States, Argentina, Australia, Canada
Source: ClinicalTrials.gov record NCT00574743. Inclusion in this directory is not an endorsement.